GLP-1 RA Lawyer – How to Bring a Lawsuit for Gastroparesis/Stomach Paralysis

GLP-1 RA lawsuits are claims for compensation by patients diagnosed with gastroparesis (stomach paralysis or “frozen stomach”) after taking the semaglutides Ozempic, Wegovy, or Rybelsus.

We allege that the manufacturer, Novo Nordisk, failed to warn doctors and patients that the semaglutides can cause gastroparesis.

Shouse Law Group represents GLP-1 RA victims throughout the United States. Our attorneys are demanding that Novo Nordisk compensate our clients for medical bills, lost wages, and pain and suffering.

You may qualify to join our GLP-1 RA litigation if you meet the following four conditions:

1. You have taken brand-name Ozempic, Wegovy, or Rybelsus; and
2. You are 75 years old or younger; and
3. You were diagnosed with gastroparesis or gastric obstruction while taking these drugs or within 30 days of stopping use; and
4. Your condition required an ER visit or admission to the hospital.

The statute of limitations to file a claim is only a year or two in some states. Therefore, victims should consult a GLP-1 RA lawsuit lawyer without delay.

In this article, our mass tort attorneys will address the following critical topics about GLP-1 RA lawsuits:

• 1. Grounds for Lawsuit
• 2. Current Litigation
• 3. Compensation
• 4. GLP-1 RAs
• 5. Gastroparesis
• 6. Eye Problems
• 7. Hiring an Attorney

1. Grounds for Lawsuit

The central claim in GLP-1 RA lawsuits is “failure to warn.”

We allege that Novo Nordisk knew – or should have known – about the heightened risk of gastroparesis/stomach paralysis. We also allege that Novo Nordisk did not include – or properly emphasize – these risks on the drug’s label or in its marketing materials.

In order to win a failure to warn lawsuit, the court must hold that this failure caused your injuries.¹

2. Current Litigation

GLP-1 RA lawsuits get consolidated into one multi-district litigation (MDL) overseen by one judge. Each lawsuit remains separate, but the MDL mechanism makes litigation and settlements more efficient because all the pretrial processes are streamlined and centralized.

The MDL number for the GLP-1 RA lawsuit is 3094, it is out of the Eastern District of Pennsylvania, and the judge is Karen S. Marston. As of mid-2025, there are about 2,000 cases in the MDL. Thousands more are expected.²

Eventually, the judge will allow a few individual cases to go to trial. The outcomes of these “bellwether trials” serve as the foundation for how the remaining lawsuits will be resolved.

3. Compensation

If your GLP-1 RA lawsuit settles, your payout will largely depend on the severity of your injuries and expenses. We fight to recover enough money to cover all of your:

• past and future medical costs,
• lost wages and lost earning potential,
• pain and suffering, and
• loss of enjoyment of life.

We foresee settlements ranging from five-to-six figures or possibly seven figures in the most serious cases.

4. GLP-1 RAs

GLP-1 RA is short for glucagon-like peptide-1 receptor agonists. The active ingredient is semaglutide, which mimics how the body’s natural GLP-1s slow food passing through the stomach.

GLP-1 RAs are prescribed to help type 2 diabetics control blood sugar and/or to help overweight people lose weight. The semaglutide with the most name recognition is Ozempic, which the FDA approved on December 5, 2017.

The following GLP-1 RAs are administered through a weekly subcutaneous injection:

• Ozempic,
• Wegovy,
• Trulicity,
• Mounjaro, and
• Zepbound.

Meanwhile, Rybelsus is an oral tablet taken daily.

The FDA Adverse Reporting System (FAERS) logged more than 100,000 semaglutide-related adverse events. As of now, none of these medications have been recalled.³

5. Gastroparesis

Studies indicate that GLP-1 RAs may increase the risk of gastroparesis, also called stomach paralysis or frozen stomach. Like it sounds, gastroparesis causes the stomach muscles to slow down or stop working altogether.

As a result, food remains in the person’s stomach for longer than normal. It is a rare condition that happens in only one of 100,000 people.⁴

Symptoms & Complications

Common symptoms of gastroparesis are:

• bloating and abdominal pain,
• nausea and vomiting,
• acid reflux,
• feeling full and loss of appetite, and/or
• weight loss.

This can then lead to complications, such as:

• dehydration,
• malnutrition,
• erratic blood glucose levels,
• ulcers,
• bleeding, and/or
• bezoars (solid food masses in the stomach), which may lead to life-threatening blockages.

Treatments

Treating gastroparesis caused by GLP-1 RAs focuses on managing symptoms and adjusting the drugs under a physician’s care. The primary strategies include:

• Dietary Changes: Eating smaller, more frequent meals that are low in fat and fiber may help digestion. Liquid or pureed foods may also be easier to digest.
• GLP-1 RA Adjustment: Lowering the semaglutide dose may help restart the stomach muscles. If symptoms are severe, discontinuing the drug may be necessary.
• Medications: Metoclopramide, erythromycin, and domperidone may help the stomach muscles work. Nausea can be managed with diphenhydramine, ondansetron, or prochlorperazine.
• Feeding tubes or gastric venting tubes: This requires surgery.
• Gastric electrical stimulation: This treatment has mixed results.⁵

6. Eye Problems

There is growing evidence that GLP-1 RAs may also cause non-arteritic anterior ischemic optic neuropathy (NAION). This is a sudden, painless loss of vision caused by a stroke-like disruption of blood flow to the front of the optic nerve, unrelated to inflammation of the arteries.

A study involving circa 350,000 diabetes patients showed that NAION risks more than doubled following two years of Ozempic treatment. It is estimated that at least one in every 10,000 people taking a GLP-1 RA may develop NAION.

As for now there is no MDL for lawsuits involving semaglutides causing NAION, so each case is being litigated separately.⁶ If you sustained eye injuries from GLP-1 RAs, we may be able to sue the drug manufacturer on your behalf if you meet the following five conditions:

1. You have taken brand-name Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, or Zepbound; and
2. You are 75 years old or younger; and
3. You were diagnosed with NAION (non-arteritic anterior ischemic optic neuropathy) while you were taking the GLP-1 RAs; and
4. You stopped taking the GLP-1 RAs once you were injured or diagnosed; and
5. You sustained any degree of permanently impaired vision.

Note that Trulicity, Mounjaro, and Zepbound are manufactured by Eli Lilly, not Novo Nordisk. 

7. Hiring an Attorney

Taking on a global pharmaceutical manufacturer like Novo Nordisk is not easy. Experienced attorneys are vital for protecting your rights and fighting for the largest settlement possible. Here is how we can help:

• Providing a Free Consultation: After reviewing your story and medical records, we will let you know whether your case is strong and right for our firm.
• Investigating Your Case: We take care of all the evidence-gathering, including amassing your medical records and consulting with medical experts.
• Handling Your Case: We compose and file all the necessary paperwork by deadline, and you should not have to step foot in a courtroom.
• Negotiating the Biggest Possible Settlement: We do not stop aggressively negotiating with opposing counsel until we reach a settlement that we believe is the most favorable resolution available under the law.

If you believe you have been harmed by GLP-1 RAs, contact us now. You have a limited time to file a claim.

---

Legal References